Search our Database of Scientific Publications and Authors

I’m looking for a

    1069 results match your criteria Extracorporeal Photopheresis

    1 OF 22

    Extracorporeal photopheresis for bronchiolitis obliterans syndrome after allogeneic stem cell transplant: An emerging therapeutic approach?
    Transfus Apher Sci 2017 Jan 13. Epub 2017 Jan 13.
    Immunohaematology and Transfusion Service, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100, Italy. Electronic address:
    Bronchiolitis obliterans syndrome (BOS) is the main manifestation of pulmonary GVHD. It has often a dramatic and fast evolution and current treatment (change or increase in immunosuppression, macrolides and inhaled therapy) is poor with high mortality rates. In this scenario, extracorporeal photopheresis (ECP) bursts as a new immunomodulatory approach with a different philosophical purpose. Read More

    The Italian registry of therapeutic apheresis - 2015.
    Transfus Apher Sci 2016 Dec 29. Epub 2016 Dec 29.
    Transfusion Medicine, Department of Padua, University-Hospital of Padua, and Italian Society of Apheresis and Cell Manipulation (SIDEM), Italy. Electronic address:
    Data collection on apheresis activities in Italy throughout 2015 including techniques, clinical indications and adverse effects was performed by means of a SidEM model questionnaire (aggregate data). These data provided by 67 Apheresis Units from 17 Italian regions, albeit rough, are sufficiently informative, mainly in comparison with previous surveys on these statistics. PEx has been the most frequent technique for plasma removal/treatment (11787 procedures) followed by LDL-apheresis (927 procedures). Read More

    Gain of CD26 expression on the malignant T-cells in relapsed erythrodermic leukemic mycosis fungoides.
    J Cutan Pathol 2017 Jan 13. Epub 2017 Jan 13.
    Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
    Loss of CD26 surface expression on the circulating malignant T-cell is the most widely accepted diagnostic marker in patients with leukemic cutaneous T-cell lymphoma (CTCL). CTCL cases with reemergence of CD7 and/or CD26 surface expression are unusual and of uncertain prognosis. We report the case of an erythrodermic leukemic mycosis fungoides patient who had achieved temporary remission after several months on multimodality immunotherapy and extracorporeal photopheresis, but who relapsed with aggressive disease phenotypically characterized by CD4+ T-cells with high CD26 expression. Read More

    A method for the quantification of 8-methoxypsoralen by mass spectrometry for offline extracorporeal photopheresis.
    Photochem Photobiol Sci 2017 Feb;16(2):193-200
    Institute for Clinical Chemistry and Laboratory Medicine, Transfusion Medicine, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.
    Background: Extracorporeal photopheresis (ECP) is an efficient method to treat various autoimmune diseases, cutaneous T-cell lymphoma, and graft-versus-host disease. It is based on the ex vivo inactivation of lymphocytes by 8-methoxypsoralen (8-MOP)/UV light treatment. Despite the adhesive, lipophilic nature of 8-MOP, no quality control is established for the ECP procedure. Read More

    Acute mechanical hemolysis as a complication of extracorporeal photopheresis in a low-weight child.
    J Clin Apher 2016 Nov 28. Epub 2016 Nov 28.
    New York-Presbyterian Hospital, New York, New York.
    Graft-versus-host disease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation with high morbidity and mortality. Extracorporeal photopheresis (ECP) is an effective therapy for treating medication-refractory GVHD, however, there is scant evidence of whether ECP can be safely performed in patients weighing less than 15 kg. Here, we report the implementation of a successful protocol to perform ECP in a 21-month-old, 10. Read More

    Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo.
    Transplantation 2016 Dec;100(12):e147-e155
    1 Hematology, Bone Marrow Transplantation Unit, Department of Clinical and Experimental Sciences, University of Brescia, Italy. 2 Immunohematology and Transfusion Medicine Unit, AO Spedali Cvili, Brescia, Italy. 3 SODc Terapia Cellulare e Medicina Trasfusionale, AOU Careggi, Firenze, Italy. 4 Divisione di Ematologia, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy. 5 SC Ematologia, Istituto Nazionale Tumori, Milano, Italy. 6 Clinica Ematologica e Unità di terapie Cellulari, DISM, Università di Udine, Italy. 7 Centro di Ricerca Emato-oncologica AIL (CREA) Brescia, AO Spedali Civili di Brescia, Italy. 8 Unità di Cellule Staminali, Istituto Europeo di Oncologia, Milano, Italy. 9 Medicina Trasfusionale, Azienda Ospedaliero-Universitaria di Udine, Italy. 10 UO di Emotrasfusione, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy. 11 Bone Marrow Transplant Unit SODc Ematologia, AOU Careggi, Firenze, Italy.
    Background: Extracorporeal photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus host disease (GVHD).

    Methods: Ninety-four patients with acute GVHD (aGVHD) (n = 45) and chronic GVHD (cGVHD) (n = 49), retrospectively recruited in 6 Italian centers, were submitted to ECP for second-line treatment. At the time of ECP, 22 (49%) and 23 (51%) of 45 patients with aGHVD were nonresponsive and in partial remission (PR) after steroids, respectively, and all the 49 patients with cGVHD were steroid refractory. Read More

    75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma.
    J Drugs Dermatol 2016 Oct;15(10):1212-1216
    Introduction: Extracorporeal photopheresis (ECP) has been used for the treatment of advanced stage or treatment refractory cutaneous T-cell lymphoma (CTCL) since 1987, and more recently has also been shown to be of benefit for earlier stage resistant CTCL. Complete response rates in prior studies of ECP in early CTCL have ranged from 0% to 40%.

    Methods: We reviewed electronic medical records of all CTCL patients seen in the University of Kansas Cancer Center between June 2007 and May 2011. Read More

    Psoralen and Ultraviolet A Light Treatment Directly Affects Phosphatidylinositol 3-Kinase Signal Transduction by Altering Plasma Membrane Packing.
    J Biol Chem 2016 Nov 29;291(47):24364-24376. Epub 2016 Sep 29.
    From the Transfusion Research Center, Belgian Red Cross-Flanders, 9000 Ghent, Belgium,
    Psoralen and ultraviolet A light (PUVA) are used to kill pathogens in blood products and as a treatment of aberrant cell proliferation in dermatitis, cutaneous T-cell lymphoma, and graft-versus-host disease. DNA damage is well described, but the direct effects of PUVA on cell signal transduction are poorly understood. Because platelets are anucleate and contain archetypal signal transduction machinery, they are ideally suited to address this. Read More


    Improving the service for patients receiving extracorporeal photopheresis using Lean principles.
    Br J Nurs 2016 Sep;25(16):917-21
    Consultant in Photopheresis, The Rotherham NHS Foundation Trust.
    The photopheresis unit where the authors work has seen an increased demand both locally and as an outreach service. A Lean assessment of the unit was undertaken to improve processing time and productivity, which in turn would improve the availability of treatment and improve patient care. The assessment indicated that there were excellent nursing standards and patient care; however, patient waiting times and treatment times were prolonged in comparison with other units. Read More

    Extracorporeal photopheresis did not prevent the development of an autoimmune disease: myasthenia gravis.
    Transfusion 2016 Dec 9;56(12):3081-3085. Epub 2016 Sep 9.
    Pediatric Bone Marrow Transplantation Unit, Medical Park Antalya Hospital, Bahçeşehir University.
    Background: Myasthenia gravis (MG) is a neuromuscular disorder characterized by an autoimmune defect in the neuromuscular junction. In most patients, the autoimmune attack is mediated by antibodies against the acetylcholine receptor (AChR) on the postsynaptic membrane. Deficient immunoregulation, including regulatory T cells, is consistently observed. Read More

    EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: AN ITALIAN MULTICENTRIC RETROSPECTIVE ANALYSIS ON 94 PATIENTS ON BEHALF OF THE GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO (GITMO).
    Transplantation 2016 Sep 8. Epub 2016 Sep 8.
    1 Chair of Hematology, Bone Marrow Transplantation Unit, Dept of Clincial and Experimental Sciences, University of Brescia, Italy 2 Immunohematology and Transfusion Medicine Unit, AO Spedali Cvili, Brescia, Italy 3 SODc Terapia Cellulare e Medicina Trasfusionale, AOU Careggi, Firenze, Italy 4 Divisione di Ematologia, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy 5 SC Ematologia, Istituto Nazionale Tumori, Milano, Italy 6 Clinica Ematologica e Unità di terapie Cellulari, DISM, Università di Udine, Italy 7 Centro di Ricerca Emato-oncologica AIL (CREA) Brescia, AO Spedali Civili di Brescia, Italy 8 Unità di Cellule Staminali, Istituto Europeo di Oncologia, Milano, Italy 9 Medicina Trasfusionale, Azienda Ospedaliero-Universitaria di Udine, Italy 10 UO di Emotrasfusione, Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy 11 Bone Marrow Transplant Unit SODc Ematologia, AOU Careggi, Firenze, Italy.
    Background: Extracorporeal photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus host disease (GVHD).

    Methods: Ninety-four patients with aGVHD (n=45) and cGVHD (n=49), retrospectively recruited in 6 Italian Centers, were submitted to ECP for second-line treatment. At the time of ECP, 22 (49%) and 23 (51%) out of 45 patients with aGHVD were non responsive (NR) and in partial remission (PR) after steroids, respectively, and all the 49 patients with cGVHD were steroid refractory. Read More

    X-Ray Psoralen Activated Cancer Therapy (X-PACT).
    PLoS One 2016 1;11(9):e0162078. Epub 2016 Sep 1.
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
    This work investigates X-PACT (X-ray Psoralen Activated Cancer Therapy): a new approach for the treatment of solid cancer. X-PACT utilizes psoralen, a potent anti-cancer therapeutic with current application to proliferative disease and extracorporeal photopheresis (ECP) of cutaneous T Cell Lymphoma. An immunogenic role for light-activated psoralen has been reported, contributing to long-term clinical responses. Read More

    Phototherapy in Scleroderma.
    Dermatol Ther (Heidelb) 2016 Dec 12;6(4):519-553. Epub 2016 Aug 12.
    Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
    Systemic and localized scleroderma are difficult to manage diseases with no accepted gold standard of therapy to date. Phototherapeutic modalities for scleroderma show promise. A PubMed search of information on phototherapy for scleroderma was conducted. Read More

    [Pansclerotic morphea with a rapidly fatal outcome in an 11-year-old girl].
    Ann Dermatol Venereol 2016 Dec 2;143(12):836-840. Epub 2016 Aug 2.
    Service de dermatologie, CHU Larrey-Toulouse, 24, chemin de Pouvourville, 31400 Toulouse, France.
    Background: Pansclerotic morphea is a poorly described but extremely debilitating variant of localized scleroderma. We report a case with a rapidly fatal outcome in an 11-year-old girl.

    Patients And Methods: An 11-year-old girl with a 2-year history of morphea presented at our institution in April 2012. Read More

    Extracorporeal photopheresis as an immunomodulatory agent: Haematocrit-dependent effects on natural killer cells.
    J Clin Apher 2016 Jul 31. Epub 2016 Jul 31.
    Department of Oncohematology, Cell Therapy Laboratory, Azienda Ospedaliero Universitaria Meyer, AOU Meyer, Florence, Italy.
    The GvHD is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Extracorporeal photopheresis (ECP) represents an alternative therapeutic strategy to immunosuppressive therapy. Although ECP is used since 1990s, the mechanism of action has not yet been completely clarified. Read More

    Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports.
    J Med Case Rep 2016 Jul 28;10:209. Epub 2016 Jul 28.
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, USA.
    Background: Patients who undergo allogeneic stem cell transplantation and subsequent radiation therapy uncommonly develop graft-versus-host disease within the irradiated area. We quantified the incidence of this complication, which is a novel contribution to the field. From 2010 to 2014, 1849 patients underwent allogeneic stem cell transplantation, and 41 (2 %) received radiation therapy afterward. Read More

    Technical comparison of four different extracorporeal photopheresis systems.
    Transfusion 2016 Oct 26;56(10):2510-2519. Epub 2016 Jul 26.
    Institute for Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
    Background: Extracorporeal photopheresis (ECP) is a therapeutic technique that combines leukapheresis and ultraviolet (UV)A irradiation of the leukapheresate after 8-methoxypsoralen treatment with subsequent retransfusion. It can be achieved with a single device (online) or by combining an apheresis machine with a separate UVA light source (offline). The comparability of both established methods is unknown. Read More

    Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee.
    J Clin Apher 2016 Jul 21. Epub 2016 Jul 21.
    Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital, Chicago, IL.
    Background: Although many apheresis centers offer extracorporeal photopheresis (ECP), little is known about current treatment practices.

    Methods: An electronic survey was distributed to assess ECP practice internationally.

    Results: Of 251 responses, 137 met criteria for analysis. Read More

    Treatment of necrobiotic xanthogranuloma - a systematic review.
    J Eur Acad Dermatol Venereol 2017 Feb 19;31(2):221-235. Epub 2016 Jul 19.
    Department of Dermatology, University Hospital, Jena, Germany.
    Necrobiotic xanthogranuloma (NXG) is an uncommon non-Langerhans cell histiocytosis involving skin and extracutaneous tissues. The lesions are usually asymptomatic and commonly appear in the periorbital area. Paraproteinemia is closely associated with NXG and its pathogenesis remains unclear. Read More

    Extracoporeal photopheresis treatment of acute graft-versus-host disease following allogeneic haematopoietic stem cell transplantation.
    F1000Res 2016 27;5. Epub 2016 Jun 27.
    Primary Immunodeficiency Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; Paediatric Haematopoietic Stem Cell Unit, Great North Children's Hospital, Newcastle upon Tyne, UK.
    Acute graft-versus-host disease (aGvHD) continues to be a major obstacle to allogeneic haematopoietic stem cell transplantation. Thymic damage secondary to aGvHD along with corticosteroids and other non-selective T lymphocyte-suppressive agents used in the treatment of aGvHD concurrently impair thymopoiesis and negatively impact on immunoreconstitution of the adaptive immune compartment and ultimately adversely affect clinical outcome. Extracorporeal photopheresis (ECP) is an alternative therapeutic strategy that appears to act in an immunomodulatory fashion, potentially involving regulatory T lymphocytes and dendritic cells. Read More

    Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.
    J Clin Apher 2016 Jun;31(3):149-62
    Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York.
    The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence-based use of therapeutic apheresis in human disease. Since the 2007 JCA Special Issue (Fourth Edition), the Committee has incorporated systematic review and evidence-based approaches in the grading and categorization of apheresis indications. This Seventh Edition of the JCA Special Issue continues to maintain this methodology and rigor to make recommendations on the use of apheresis in a wide variety of diseases/conditions. Read More

    Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells.
    Transfus Apher Sci 2016 Aug 6;55(1):146-52. Epub 2016 Jun 6.
    Department of Dermatology, Yale University, New Haven, CT 06520. Electronic address:
    Extracorporeal photochemotherapy (ECP), or photopheresis, is distinguished by the specificity of the clinically potent immunologic reactions it initiates or regulates. The selectivity of ECP-induced immunoprotection for the malignant clone in cutaneous T cell lymphoma (CTCL), and for the pathogenic clones in allograft rejection and graft-versus-host disease (GVHD), has suggested a central mechanistic role for dendritic antigen presenting cells (DC). Discovery of ECP's induction of monocyte-derived DC, via monocyte signaling by ECP-plate activated platelets, and the absolute dependency of experimental ECP on such induced DC, supports that premise. Read More

    Selective photodepletion of malignant T cells in extracorporeal photopheresis with selenorhodamine photosensitizers.
    Bioorg Med Chem 2016 Sep 2;24(17):3918-31. Epub 2016 Jun 2.
    Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY 14260, United States. Electronic address:
    Extracorporeal photopheresis (ECP) has been used successfully in the treatment of erythrodermic cutaneous T cell lymphoma (CTCL), and other T cell-mediated disorders. Not all patients obtain a significant or durable response from ECP. The design of a selective photosensitizer that spares desirable lymphocytes while targeting malignant T cells may promote cytotoxic T cell responses and improve outcomes after ECP. Read More

    Comparison of two automated mononuclear cell collection systems in patients undergoing extracorporeal photopheresis: a prospective crossover equivalence study.
    Transfusion 2016 Aug 1;56(8):2078-84. Epub 2016 Jun 1.
    Immunohaematology and Transfusion Service, Apheresis and Cell Therapy Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
    Background: Extracorporeal photopheresis (ECP) is an effective cell therapy employed in several diseases, including graft versus host disease (GVHD) and organ rejection. When ECP is performed using an off-line technique, mononuclear cell (MNC) collection by leukapheresis is necessary for further manipulation (addition of 8-methoxypsoralen and ultraviolet A irradiation before reinfusion to the patient). We report the results of the first crossover equivalence study on yield and purity of MNCs collected from patients undergoing ECP with two different automated systems: MNC and CMNC (working with intermittent and continuous-flow collection, respectively), released by Terumo BCT. Read More

    How I treat mycosis fungoides and Sézary syndrome.
    Blood 2016 Jun 5;127(25):3142-53. Epub 2016 May 5.
    Division of Cancer Medicine, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
    Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma variant and is closely related to a rare leukemic variant, Sézary syndrome (SS). MF patients at risk of disease progression can now be identified and an international consortium has been established to address the prognostic relevance of specific biologic factors and define a prognostic index. There are a lack of randomized clinical trial data in MF/SS and evidence is based on a traditional "stage-based" approach; treatment of early-stage disease (IA-IIA) involves skin directed therapies which include topical corticosteroids, phototherapy (psoralen with UVA or UVB), topical chemotherapy, topical bexarotene, and radiotherapy including total skin electron beam therapy. Read More

    Regulatory T Cells in Chronic Graft-Versus-Host Disease After Extracorporeal Photopheresis: Correlation With Skin and Global Organ Responses, and Ability to Taper Steroids.
    Transplantation 2017 Jan;101(1):204-211
    1 Haematology Department and Photopheresis Unit, Rotherham NHS Foundation Trust, Rotherham, South Yorkshire, United Kingdom. 2 Medical Statistics Group, School of Health and Related Research (ScHARR), The University of Sheffield Sheffield, South Yorkshire, United Kingdom. 3 Knowledge and Intelligence Team (East Midlands), Public Health England, Sheffield, United Kingdom.
    Background: Induction of immune tolerance by an increase in regulatory T (Treg) cells after extracorporeal photopheresis (ECP) is thought to contribute to how ECP exerts its therapeutic effect in patients with chronic graft-versus-host disease (cGvHD). We investigated whether percentages and absolute counts of Treg cells changed post-ECP, and examined correlation with response.

    Methods: Absolute counts and % of CD4+ T cells and Treg cells (CD4 + CD25 + FOXP3 + CD127dim/-) were evaluated using flow cytometry in 32 patients with cGvHD treated by ECP for a minimum of 3 months, and up to 12 months. Read More

    Extracorporeal Photopheresis for Non-skin GvHD.
    Anticancer Res 2016 Mar;36(3):1395-6
    Department of Dermatology, Saarland University Hospital, Homburg, Germany.
    Graft versus host disease (GvHD) is one of the most feared adverse events of allogeneic hematopoietic stem cell transplantation. In severe grades of GvHD patients die from infections due to impairment of their immune defense or therapy-refractory involvement of intestines, liver and lung. Extracorporeal photopheresis is an effective treatment for acute and chronic graft versus host disease without severe impairment of the recipient's immune system. Read More

    An alternative mini buffy coat preparation method for adult patients with extracorporeal photopheresis contraindications.
    J Clin Apher 2017 Feb 4;32(1):12-15. Epub 2016 Mar 4.
    Department for Blood Group Serology and Transfusion Medicine, SALK - Paracelsus Medical University (PMU), Salzburg, Austria.
    Background: Extracorporeal photopheresis (ECP) is an important cell-based therapy for various diseases but is limited to patients eligible for apheresis. We developed an alternative mini buffy coat (BC) preparation method using the Spectra Optia® apheresis system and compared its efficacy of white blood cell (WBC) recovery with the standard mini BC preparation method already established for pediatric patients.

    Methods: Whole blood (450 ± 45 mL) samples were collected from 30 randomly selected healthy volunteer blood donors and divided into two groups. Read More

    Ultraviolet blood irradiation: Is it time to remember "the cure that time forgot"?
    J Photochem Photobiol B 2016 Apr 5;157:89-96. Epub 2016 Feb 5.
    Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA. Electronic address:
    Ultraviolet blood irradiation (UBI) was extensively used in the 1940s and 1950s to treat many diseases including septicemia, pneumonia, tuberculosis, arthritis, asthma, and even poliomyelitis. The early studies were carried out by several physicians in USA and published in the American Journal of Surgery. However, with the development of antibiotics, the use of UBI declined and it has now been called "the cure that time forgot. Read More

    Extracorporeal photopheresis in solid organ transplant-associated acute graft-versus-host disease.
    Transfusion 2016 Apr 18;56(4):962-9. Epub 2016 Feb 18.
    Department of Medicine.
    Background: Extracorporeal photopheresis (ECP) culls pathogenic T lymphocytes, be these the clones of cutaneous T-cell lymphoma, or mediators of chronic graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT-GVHD). Whether or not ECP may have an effect in the rarer instances of solid organ transplantation-associated GVHD (SOT-GVHD) is unclear. Mortality rates in SOT-GVHD rival those of transfusion-associated GVHD, with fatalities preceded by pancytopenia and peripheral blood chimerism (PBC) levels exceeding 20%. Read More

    Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.
    World J Gastrointest Pharmacol Ther 2016 Feb;7(1):5-20
    Gerda C Leitner, University Clinic for Blood Group Serology and Transfusion Medicine, Medical University, 1090 Vienna, Austria.
    Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory conditions mainly of the colon and small intestine. Crohn's disease (CD) and ulcerative colitis (UC) are the most frequent types of IBD. IBD is a complex disease which arises as a result of the interaction of environmental, genetic and immunological factors. Read More

    [THE DYNAMICS OF IMMUNOLOGICAL RESULTS OF PATIENTS WITH T-CELL SKIN LYMPHOMAS AND PSORIASIS BY THE THERAPY OF ACTIVATION MECHANISMS SANOGENESIS METHODS].
    Lik Sprava 2015 Apr-Jun(3-4):31-8
    The therapy T-cell skin lymphoma and psoriasis by the application of activation mechanisms sanogenesis methods, such as: original--a treatment plasmapheresis, a standard heparin infusion; used for the first time--wobenzym; solutions of acid acetic food and sodium bicarbonate; known--the basic sanitations of concomitant diseases, photopheresis caused remissions in 79.6% patients with different stages T-cell skin lymphoma (observed over an 8-year span), and in 67% of patients with psoriasis (observed over an 6-year span). Depuration reactions (phagocytosis, pinocytosis, toxin neutralization) has been activated by detoxication of treatment plasmapheresis and heparin infusions. Read More

    Establishing an institutional therapeutic apheresis registry.
    J Clin Apher 2016 Dec 23;31(6):516-522. Epub 2016 Jan 23.
    Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, Arizona.
    Apheresis was first performed as a therapeutic procedure in the 1950s. The first national therapeutic apheresis (TA) registry was established in Canada in 1981 and other national registries followed, including two attempts at establishing an international TA registry. There is no national registry in the United States. Read More

    [Chronic rejection: Differences and similarities in various solid organ transplants].
    Internist (Berl) 2016 Jan;57(1):25-37
    Institut für Pathologie, Medizinische Hochschule Hannover, Hannover, Deutschland.
    In this paper, chronic rejections after transplantation of the lungs, heart, liver, and kidney are described. Chronic allograft dysfunction (CAD) plays an important role in all of these transplantations and has a significant influence on patient survival. The pathophysiological reasons for CAD varies greatly in the various organs. Read More

    [Sézary syndrome treated with extracorporeal photopheresis: Report of one case].
    Rev Med Chil 2015 Nov;143(11):1449-58
    Sézary syndrome (SS) is an unusually aggressive T- cell lymphoma characterized by the triad of erythroderma, the presence of more than 1,000 Sézary cells in peripheral blood and lymphadenopathies. It is accompanied by generalized pruritus and poor quality of life. The management of SS depends on its stage, patient comorbidities, and treatment availability. Read More

    Limited thymic recovery after extracorporeal photopheresis in a low-body-weight patient with acute graft-versus-host disease of the skin.
    J Allergy Clin Immunol 2016 Jun 9;137(6):1890-1893.e1. Epub 2015 Dec 9.
    Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom. Electronic address:

    Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.
    Cochrane Database Syst Rev 2015 Dec 15(12):CD009898. Epub 2015 Dec 15.
    Pediatric Nephrology, University Children's Hospital, Steinwiesstrasse 75, Zurich, Switzerland, 8032.
    Background: Chronic graft-versus-host disease (GvHD) is a major cause of morbidity and mortality after haematopoietic stem cell transplantation occurring in 6% to 65% of the recipients. Currently, the therapeutic mainstay for chronic GvHD are corticosteroids that are frequently combined with other immunosuppressive agents in people with steroid-refractory manifestations. There is no established standard treatment for steroid-refractory chronic GvHD. Read More

    Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients.
    Cochrane Database Syst Rev 2015 Dec 15(12):CD009759. Epub 2015 Dec 15.
    Pediatric Nephrology, University Children's Hospital, Steinwiesstrasse 75, Zurich, Switzerland, 8032.
    Background: Acute graft-versus-host disease (aGvHD) is a major cause of morbidity and mortality after haematopoietic stem cell transplantation (HSCT) occurring in 8% to 59% of the recipients. Currently, the therapeutic mainstay for aGvHD is corticosteroids. However, there is no established standard treatment for steroid-refractory aGvHD. Read More

    Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.
    Biol Blood Marrow Transplant 2016 May 6;22(5):862-8. Epub 2015 Nov 6.
    Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, Michigan; Blood and Marrow Transplant Program, Icahn School of Medicine at Mount Sinai, New York, New York.
    Reduced-intensity conditioning (RIC) regimens minimize early toxicity after allogeneic hematopoietic cell transplantation (HCT) by placing greater reliance on establishing a graft-versus-leukemia effect (GVL). Because graft-versus-host disease (GVHD) and GVL are tightly linked, inhibition of T cell populations that cause GVHD may lead to an unintended increased risk of relapse in the RIC setting. Although not completely understood, etanercept and extracorporeal photopheresis (ECP) are thought to ameliorate GVHD without direct T cell inhibition. Read More

    [Problems and prospects of creation of extracorporal systems for support of functional livers status].
    Biomed Khim 2015 Sep-Oct;61(5):545-59
    South-Ural State Medical University, Chelyabinsk, Russia.
    The review considers features of efferent therapy employing extracorporeal systems, the devices known as "artificial liver" and "bioartificial liver" in the treatment of liver insufficiency. Analysis of literature data shows the need for further development of these biomedical studies and the search for optimal solutions in the selection of the source of hepatocytes, the development of bioreactors and biomaterials forming the basis of devices like "bioartificial liver". Taking into consideration certain advantages and disadvantages typical for various methods of extracorporeal support of the functional state of the liver one can evaluate prior experience in the treatment of liver diseases and approaches to the development of new, more effective medical technologies. Read More

    Response of steroid-refractory chronic graft-versus-host disease to extracorporeal photopheresis correlates with the dose of CD3+ lymphocytes harvested during early treatment cycles.
    Transfusion 2016 Feb 10;56(2):505-10. Epub 2015 Oct 10.
    Transfusion Medicine Department, Ospedale Niguarda Ca' Granda, Milan, Italy.
    Background: Extracorporeal photopheresis (ECP) is a recognized second-line treatment for steroid-refractory chronic graft-versus-host disease (cGVHD). Treatment course is usually long, expensive, and demanding for patients, so predictors for response are needed. We carried out a retrospective study on cGVHD patients treated at our institution with the aim to identify a possible correlation between apheretic yields composition and probability of response. Read More

    Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Dermatol Clin 2015 Oct 29;33(4):765-76. Epub 2015 Jul 29.
    Division of Dermatology, Vanderbilt University School of Medicine, 701 Thompson Ln, Ste 26300, Nashville, TN 37204, USA. Electronic address:
    Extracorporeal photopheresis (ECP) is an immunomodulating procedure that leads to an expansion of peripheral blood dendritic cell populations and an enhanced TH1 immune response in cutaneous T-cell lymphoma (CTCL). Because of its excellent side effect profile and moderate efficacy, ECP is considered first-line therapy for erythrodermic mycosis fungoides (MF) and Sézary syndrome. Patients with a measurable but low blood tumor burden are most likely to respond to ECP, and the addition of adjunctive immunostimulatory agents may also increase response rates. Read More

    [Update on extracorporeal photopheresis].
    Hautarzt 2015 Nov;66(11):804-9
    Universitätsklinik für Dermatologie, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich.
    Extracorporeal photopheresis (ECP) is a treatment approach that combines leukapheresis with photochemotherapy and is derived from PUVA; with this procedure, nucleated cells such as lymphocytes and monocytes are extracorporeally irradiated with UVA light after photosensitization. ECP is an effective treatment modality with few side effects that in recent years has been expanded to treat a range of indications. It has been proven effective in the treatment of cutaneous T cell lymphoma and is being increasing used in other lymphocyte-mediated, autoimmune and inflammatory diseases that are associated with proliferation of autoreactive T cells. Read More

    Plasmapheresis, Photopheresis, and Endovenous Immunoglobulin in Acute Antibody-mediated Rejection in Kidney Transplantation.
    Transplant Proc 2015 Sep;47(7):2142-4
    UOC Chirurgia Generale e Trapianti di Organo, Sapienza, Rome, Italy.
    Introduction: Acute antibody-mediated rejection (AAMR) is the subject of much research. It is diagnosed by C4d staining at biopsy and circulating donor-specific antibodies (DSA). The combination of intensive plasmapheresis and intravenous immunoglobulin (IVIG) has been recognized as an effective treatment for AAMR. Read More

    [On Individualization of Therapeutic Doses of Optical Radiation according to Changes in Parameters of Blood Oxygenation].
    Biofizika 2015 May-Jun;60(3):534-41
    The effect of in vivo laser irradiation by optical radiation on blood from different patients is studied. The objects of research were three series of blood samples from patients whose treatment course included extracorporeal UV blood irradiation, intravenous laser blood irradiation and supra-venous blood laser irradiation. Before and after irradiation the results on optic oximetry and gas content of venous blood were compared. Read More

    1 OF 22